Jupiter Neurosciences, Inc. (JUNS)Healthcare | Biotechnology | Jupiter, United States | NasdaqCM
0.48 USD
+0.02
(3.478%)
⇧
(April 21, 2026, 10:38 a.m.
EDT)
Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:11 p.m. EDT
JUNS is a high-risk speculative name with severe technical weakness (forecasting -23%adjustment over 45 days) and deteriorating fundamentals. Despite recent news regarding Nugevia and regulatory compliance, the negative stock price performance (e.g., 23% drop from 52-week highs) combined with cash burn, losses, and a large premium over book value makes it an avoid candidate for both short and long-term investors. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.285468 |
| AutoTheta | 0.387390 |
| MSTL | 0.599788 |
| AutoETS | 0.613206 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 2.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.014 |
| Excess Kurtosis | 0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.001 |
| Market Cap | 17,269,876 |
| Forward P/E | 7.93 |
| Website | https://jupiterneurosciences.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.28125 |
| Address1 | 1,001 North US Highway 1 |
| Address2 | Suite 504 |
| All Time High | 19.51 |
| All Time Low | 0.306 |
| Ask | 0.35 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 104,240 |
| Average Daily Volume3 Month | 328,242 |
| Average Volume | 328,242 |
| Average Volume10Days | 104,240 |
| Bid | 0.4487 |
| Bid Size | 2 |
| Book Value | 0.002 |
| City | Jupiter |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.476 |
| Current Ratio | 0.652 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.48 |
| Day Low | 0.45 |
| Display Name | Jupiter Neurosciences |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 835.903 |
| Enterprise Value | 18,219,348 |
| Eps Forward | 0.06 |
| Eps Trailing Twelve Months | -0.25 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.44928 |
| Fifty Day Average Change | 0.026720017 |
| Fifty Day Average Change Percent | 0.059472974 |
| Fifty Two Week Change Percent | -28.125 |
| Fifty Two Week High | 3.33 |
| Fifty Two Week High Change | -2.8539999 |
| Fifty Two Week High Change Percent | -0.85705703 |
| Fifty Two Week Low | 0.306 |
| Fifty Two Week Low Change | 0.17000002 |
| Fifty Two Week Low Change Percent | 0.55555564 |
| Fifty Two Week Range | 0.306 - 3.33 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,733,236,200,000 |
| Float Shares | 18,330,377 |
| Forward Eps | 0.06 |
| Forward P E | 7.933334 |
| Free Cashflow | -2,314,987 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -2,069,009 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.51335 |
| Held Percent Institutions | 0.04435 |
| Implied Shares Outstanding | 36,281,252 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-12-03 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida. |
| Long Name | Jupiter Neurosciences, Inc. |
| Market | us_market |
| Market Cap | 17,269,876 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_374998760 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -8,644,897 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 16,689,375 |
| Open | 0.45 |
| Operating Cashflow | -5,413,736 |
| Operating Margins | -128.86699 |
| Payout Ratio | 0.0 |
| Phone | 561 406 6154 |
| Previous Close | 0.46 |
| Price Hint | 4 |
| Price To Book | 238.0 |
| Price To Sales Trailing12 Months | 792.34155 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.513 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.016000003 |
| Regular Market Change Percent | 3.4782615 |
| Regular Market Day High | 0.48 |
| Regular Market Day Low | 0.45 |
| Regular Market Day Range | 0.45 - 0.48 |
| Regular Market Open | 0.45 |
| Regular Market Previous Close | 0.46 |
| Regular Market Price | 0.476 |
| Regular Market Time | 1,776,782,309 |
| Regular Market Volume | 12,830 |
| Return On Assets | -0.94641 |
| Return On Equity | -7.38831 |
| Revenue Per Share | 0.001 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 36,281,252 |
| Shares Percent Shares Out | 0.0034999999 |
| Shares Short | 126,917 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 215,988 |
| Short Name | Jupiter Neurosciences, Inc. |
| Short Percent Of Float | 0.006 |
| Short Ratio | 0.66 |
| Source Interval | 15 |
| State | FL |
| Symbol | JUNS |
| Total Cash | 3,789,342 |
| Total Cash Per Share | 0.104 |
| Total Debt | 5,319,315 |
| Total Revenue | 21,796 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.11295 |
| Two Hundred Day Average Change | -0.63694996 |
| Two Hundred Day Average Change Percent | -0.5723078 |
| Type Disp | Equity |
| Volume | 12,830 |
| Website | https://jupiterneurosciences.com |
| Zip | 33,477 |